| 722 |
Complications after TAVI: VARC Definitions, Frequency, and Management Considerations |
Patrick W. Serruys |
May. 12. 11 |
| 721 |
TAVI Perspectives from the European Theatre: New Indications and Multiple Devices |
Eberhard Grube |
May. 12. 11 |
| 720 |
Life after PARTNER (Inoperable and “High Risk” Cohorts): Will TAVI Therapy Change Guidelines for AS Patients? |
Martin Bert Leon |
May. 12. 11 |
| 719 |
Behind Closed Doors: Functions of a Data Safety Monitoring Board |
Roxana Mehran |
May. 04. 10 |
| 718 |
Importance of Endpoint Adjudication (Clinical Events Committees) and Core Laboratories |
Donald E. Cutlip |
May. 04. 10 |
| 717 |
Nuances of Clinical Trials: Trial Size, Power Analysis, Sub Groups |
David Joel Cohen |
May. 04. 10 |
| 716 |
Types of Clinical Trials in Cardiology: The Rationale for Trial Design |
Roxana Mehran |
May. 04. 10 |
| 715 |
From DES to Percutaneous Valves: What Interventional Doctors Need to Know about Regulatory Barriers and Solutions to Global Device Evaluation |
Mitchell W. Krucoff |
May. 04. 10 |
| 714 |
Experience and Opportunities for Asia-PAC in Global Device Studies |
Takaaki Isshiki |
May. 04. 10 |
| 713 |
Global Evaluation of Left Main PCI: The Time Has Come |
Chuck Simonton |
May. 04. 10 |
